[{"id":"737bf8ac-224d-4890-9289-ef1407053b41","acronym":"VITAL","url":"https://clinicaltrials.gov/study/NCT02658487","created_at":"2021-01-18T12:56:58.878Z","updated_at":"2024-07-02T16:35:06.085Z","phase":"Phase 2","brief_title":"Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT02658487 - VITAL","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SRC","pipe":"","alterations":" ","tags":["SRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"6e2635e5-8b6b-4276-85a3-1ead01efd26e","acronym":"BIG-1","url":"https://clinicaltrials.gov/study/NCT02416388","created_at":"2021-01-18T11:32:41.418Z","updated_at":"2024-07-02T16:36:39.837Z","phase":"Phase 2/3","brief_title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","source_id_and_acronym":"NCT02416388 - BIG-1","lead_sponsor":"University Hospital, Angers","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • dexamethasone • idarubicin hydrochloride • cyclosporine • Qinprezo (vosaroxin)"],"overall_status":"Recruiting","enrollment":" Enrollment 3100","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":"","study_completion_date":"","last_update_posted":"2020-10-20"},{"id":"75427955-b93e-415c-9f67-79663c7d466d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00408603","created_at":"2021-01-18T01:25:56.750Z","updated_at":"2024-07-02T16:37:19.503Z","phase":"Phase 2","brief_title":"Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT00408603","lead_sponsor":"Sunesis Pharmaceuticals","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Qinprezo (vosaroxin)"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 12/20/2006","start_date":" 12/20/2006","primary_txt":" Primary completion: 06/09/2010","primary_completion_date":" 06/09/2010","study_txt":" Completion: 06/09/2010","study_completion_date":" 06/09/2010","last_update_posted":"2017-07-27"}]